<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02938273</url>
  </required_header>
  <id_info>
    <org_study_id>N16BIR</org_study_id>
    <nct_id>NCT02938273</nct_id>
  </id_info>
  <brief_title>Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)</brief_title>
  <official_title>Bioimmunoradiotherapy (BIR) With Concurrent Avelumab, Cetuximab and Radiotherapy as First Line Treatment in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Feasibility Study in Patients Unfit for Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label phase IB trial with Bioimmunoradiotherapy, i.e. concurrent radiotherapy&#xD;
      with intravenous administration of cetuximab and avelumab followed by avelumab maintenance&#xD;
      therapy in patients with locally advanced head and neck cancer, unfit for cisplatin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurence of grade 3-5 toxicity in new combination</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>according to CTC 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>at week 10 and week 26 of treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>differences in tumor microenvironment</measure>
    <time_frame>prior to treatment and at day 14</time_frame>
    <description>investigate therapy induced changes in tumor microenvironment in tissue biopsies through immunochemistry</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Bioimmunoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent Radiation therapy (i.e. 5 times a week, 7 weeks, total dose 70 Gy) with cetuximab (loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7) and Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months (wk 8,10, 12, 14, 16, 18, 20, 22, 24, 26.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avelumab</intervention_name>
    <description>Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months</description>
    <arm_group_label>Bioimmunoradiotherapy</arm_group_label>
    <other_name>MSB0010718C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>5 times a week, 7 weeks, total dose 70 Gy</description>
    <arm_group_label>Bioimmunoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7</description>
    <arm_group_label>Bioimmunoradiotherapy</arm_group_label>
    <other_name>erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to provide written informed consent for the trial.&#xD;
&#xD;
          -  Be ≥18 years of age on day of signing informed consent.&#xD;
&#xD;
          -  WHO Performance Status 0,1 or 2&#xD;
&#xD;
          -  Have histologically confirmed Locally Advanced (i.e. stage III or IV) head and neck&#xD;
             squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx.&#xD;
&#xD;
          -  Unfit for concurrent chemoradiation with cisplatin, e.g. GFR &lt; 60 ml/min,&#xD;
             cardiovascular co-morbidity, hearing loss or polyneuropathy or written refusal for&#xD;
             treatment with chemotherapy&#xD;
&#xD;
          -  Be willing to provide tissue for tumor microenvironment analysis from archival tumor&#xD;
             material (i.e. formalin fixed, paraffin embedded (FFPE) tumor tissue block not older&#xD;
             than 42 days before start of treatment) or newly obtained core or excisional biopsy,&#xD;
             and willingness to provide a core or excisional biopsy at day 14 (±2 days) after start&#xD;
             of treatment.&#xD;
&#xD;
          -  Have at least one measurable lesion as defined by RECIST 1.1.&#xD;
&#xD;
          -  Be willing and able to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
          -  Demonstrate adequate organ function, i.e. adequate bone marrow function, including:&#xD;
&#xD;
               1. Absolute Neutrophil Count (ANC) ≥1.5 x 109/L;&#xD;
&#xD;
               2. Platelets ≥100 x 109/L;&#xD;
&#xD;
               3. Hemoglobin ≥6 mmol/L. Adequate renal function, i.e. estimated creatinine&#xD;
                  clearance ≥30 mL/min as calculated using the Cockcroft-Gault (CG) equation (or&#xD;
                  local institutional standard method).&#xD;
&#xD;
        Adequate liver function, including:&#xD;
&#xD;
          1. Total serum bilirubin ≤1.5 x ULN;&#xD;
&#xD;
          2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN or AST&#xD;
             and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the&#xD;
             liver).&#xD;
&#xD;
               -  Have a negative serum pregnancy test at screening (for females of childbearing&#xD;
                  potential).&#xD;
&#xD;
               -  Both male and female subjects should agree to use highly effective contraception&#xD;
                  if the risk of conception exists. (Note: The effects of the trial drug on the&#xD;
                  developing human fetus are unknown; thus, women of childbearing potential and men&#xD;
                  able to father a child must agree to use 2 highly effective contraception,&#xD;
                  defined as methods with a failure rate of less than 1 % per year.) Highly&#xD;
                  effective contraception is required throughout the study and for at least 120&#xD;
                  days after Avelumab treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Prior treatment with: Systemic therapy, radiotherapy or surgery directed at locally&#xD;
        advanced SCCHN. Immunotherapy with IL-2, IFN-α, or anti-PD-1, anti-PD-L1, anti-PD-L2,&#xD;
        anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody&#xD;
        (including ipilimumab), or any other antibody or drug specifically targeting T-cell&#xD;
        co-stimulation or immune checkpoint pathways.&#xD;
&#xD;
          -  A diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other&#xD;
             form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 7 days prior to&#xD;
             registration, except the following:&#xD;
&#xD;
               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g.&#xD;
                  intra-articular injection);&#xD;
&#xD;
               -  Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or&#xD;
                  equivalent;&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (eg, CT scan&#xD;
                  premedication).&#xD;
&#xD;
          -  Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥3), any&#xD;
             history of anaphylaxis, or uncontrolled asthma (i.e., 3 or more features of partially&#xD;
             controlled asthma Global Initiative for Asthma 2011.&#xD;
&#xD;
          -  Known prior or suspected hypersensitivity to study drugs or any component in their&#xD;
             formulations.&#xD;
&#xD;
          -  Diagnosis of any other malignancy within 5 years prior to start of treatment except&#xD;
             for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ&#xD;
             of the breast or of the cervix, or low-grade (Gleason 6 or below) prostate cancer on&#xD;
             surveillance with no plans for treatment intervention (e.g. surgery, radiation, or&#xD;
             castration).&#xD;
&#xD;
          -  Significant acute or chronic infections including, among others:&#xD;
&#xD;
               -  Known history of testing positive test for human immunodeficiency virus (HIV) or&#xD;
                  known acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
               -  Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV&#xD;
                  antibody tested positive)&#xD;
&#xD;
          -  Prior organ transplantation, including allogeneic stem cell transplantation&#xD;
&#xD;
          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory&#xD;
             agent, except the following:&#xD;
&#xD;
               1. Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease&#xD;
                  not requiring immunosuppressive treatment&#xD;
&#xD;
               2. Subjects requiring hormone replacement with corticosteroids if the steroids are&#xD;
                  administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or&#xD;
                  10 mg equivalent prednisone per day&#xD;
&#xD;
               3. Administration of steroids through a route known to result in a minimal systemic&#xD;
                  exposure (topical, intranasal, intro-ocular, or inhalation)&#xD;
&#xD;
          -  Persisting toxicity related to prior therapy of Grade &gt;1; however, alopecia and&#xD;
             sensory neuropathy Grade ≤ 2 is acceptable&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known alcohol or drug abuse&#xD;
&#xD;
          -  All other significant diseases (for example, inflammatory bowel disease, uncontrolled&#xD;
             asthma), which, in the opinion of the Investigator, might impair the subject's&#xD;
             tolerance of trial treatment&#xD;
&#xD;
          -  Any psychiatric condition that would prohibit the understanding or rendering of&#xD;
             informed consent&#xD;
&#xD;
          -  Vaccination within 4 weeks of the first dose of avelumab and while on trial is&#xD;
             prohibited except for administration of inactivated vaccines (for example, inactivated&#xD;
             influenza vaccines).&#xD;
&#xD;
          -  Any of the following in the previous 6 months: myocardial infarction, severe/unstable&#xD;
             angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure,&#xD;
             cerebrovascular accident, transient ischemic attack, deep vein thrombosis or&#xD;
             symptomatic pulmonary embolism.&#xD;
&#xD;
          -  Subjects with brain metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Paul de Boer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

